文献速递心脑血管急症消化、代谢与肾脏急症

非空腹与空腹血脂水平与主要冠脉事件风险的关联:盎格鲁-斯堪的纳维亚心脏终点试验-降脂分支

Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm.
PubMed 文献 · JAMA Intern Med · 2019-01-01
一句话结论同一人群中非空腹与空腹血脂对冠脉和ASCVD事件的关联相似,非空腹血脂可用于ASCVD风险筛查和他汀起始评估。

该研究为盎格鲁-斯堪的纳维亚心脏终点试验-降脂分支的事后前瞻性随访,纳入8270例受试者(其中6855例无既往血管疾病),非空腹与空腹血脂相隔4周测量,中位随访3.3年。主要终点为主要冠脉事件(212例),次要终点为ASCVD事件(351例)。非空腹与空腹血脂的关联相似,例如每40 mg/dL低密度脂蛋白胆固醇的校正HR分别为1.32(95%CI 1.08-1.61)和1.28(95%CI 1.07-1.55);一级预防组分别为1.42(95%CI 1.13-1.78)和1.37(95%CI 1.11-1.69)。两种血脂分类ASCVD风险类别的 concordance 为94.8%。作者认为常规非空腹血脂测量可能有助于促进ASCVD风险筛查和治疗,包括考虑何时启动他汀治疗。

要点

  • 同一人群中非空腹与空腹血脂对主要冠脉事件的关联相似:每40 mg/dL低密度脂蛋白胆固醇校正HR分别为1.32(95%CI 1.08-1.61)和1.28(95%CI 1.07-1.55)。
  • 一级预防人群(6855例无既往血管疾病)中,非空腹与空腹血脂的关联也相似:每40 mg/dL低密度脂蛋白胆固醇校正HR分别为1.42(95%CI 1.13-1.78)和1.37(95%CI 1.11-1.69)。
  • 非空腹与空腹血脂分类ASCVD风险类别的 concordance 高达94.8%,提示用非空腹替代空腹测量对风险分类影响小。
  • 作者认为常规非空腹血脂测量可能有助于促进ASCVD风险筛查和治疗,包括考虑何时启动他汀治疗。

适用人群与场景

  • 盎格鲁-斯堪的纳维亚心脏终点试验-降脂分支的8270例受试者,其中6855例无既往血管疾病(一级预防人群)。
  • 受试者中82.1%为男性,平均(标准差)年龄63.4(8.5)岁。

研究设计与关键结果

  • 研究类型为随机临床试验的事后前瞻性随访,纳入8270例受试者,非空腹与空腹血脂相隔4周测量,中位随访3.3年(四分位距2.8-3.6年)。
  • 主要终点为主要冠脉事件(非致死性心肌梗死和致死性冠心病,共212例事件);次要终点为ASCVD事件(包括心肌梗死、卒中和ASCVD死亡,共351例事件)。
  • 每40 mg/dL低密度脂蛋白胆固醇的校正HR:非空腹1.32(95%CI 1.08-1.61;P=0.007),空腹1.28(95%CI 1.07-1.55;P=0.008)。
  • 一级预防组每40 mg/dL低密度脂蛋白胆固醇的校正HR:非空腹1.42(95%CI 1.13-1.78;P=0.003),空腹1.37(95%CI 1.11-1.69;P=0.003)。
  • 按随机治疗组(阿托伐他汀钙10 mg/d或安慰剂)分层结果一致,ASCVD事件结果相似。
  • 非空腹与空腹血脂分类ASCVD风险类别的 concordance 为94.8%。

证据类型、等级与局限

  • 证据类型:随机临床试验的事后前瞻性随访。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为常规测量非空腹血脂可能有助于促进ASCVD风险筛查和治疗,包括考虑何时启动他汀治疗。
  • 对于需要评估ASCVD风险和他汀起始的个体,非空腹与空腹血脂对冠脉和ASCVD事件的关联相似,非空腹与空腹分类ASCVD风险类别的 concordance 为94.8%。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Recent guidelines have recommended nonfasting for routine testing of lipid levels based on comparisons of nonfasting and fasting populations. However, no previous study has examined the association of cardiovascular outcomes with fasting vs nonfasting lipid levels measured in the same individuals.

OBJECTIVE: To compare the association of nonfasting and fasting lipid levels with prospectively ascertained coronary and vascular outcomes and to evaluate whether a strategy of using nonfasting instead of fasting lipid level measurement would result in misclassification of risk for individuals undergoing evaluation for initiation of statin therapy.

DESIGN, SETTING, AND PARTICIPANTS: This post hoc prospective follow-up of a randomized clinical trial included 8270 of 10 305 participants from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA) with nonfasting and fasting lipid levels measured 4 weeks apart (including 6855 participants with no prior vascular disease) (median follow-up, 3.3 years; interquartile range, 2.8-3.6 years). Data were collected from February 1, 1998, to December 31, 2002, and analyzed from February 1, 2016, to November 30, 2018. Multivariable Cox models, adjusted for cardiovascular risk factors, were calculated for 40-mg/dL (1-mmol/L) higher values of nonfasting and fasting lipids.

MAIN OUTCOMES AND MEASURES: The trial's primary end point consisted of major coronary events (nonfatal myocardial infarction [MI] and fatal coronary heart disease [212 events]). Secondary analyses examined atherosclerotic cardiovascular disease (ASCVD) events (including MI, stroke, and ASCVD death [351 events]).

RESULTS: Among the 8270 participants (82.1% male; mean [SD] age, 63.4 [8.5] years), nonfasting samples had modestly higher triglyceride levels and similar cholesterol levels compared to fasting samples. Associations of nonfasting lipid levels with coronary events were similar to those for fasting lipid levels. For example, adjusted hazard ratios (HRs) per 40-mg/dL of low-density lipoprotein cholesterol were 1.32 (95% CI, 1.08-1.61; P = .007) for nonfasting levels and 1.28 (95% CI, 1.07-1.55; P = .008) for fasting levels. For the primary prevention group, adjusted HRs were 1.42 (95% CI, 1.13-1.78; P = .003) for nonfasting levels and 1.37 (95% CI, 1.11-1.69; P = .003) for fasting levels. Results were consistent by randomized treatment arm (atorvastatin calcium, 10 mg/d, or placebo) and similar for ASCVD events. Concordance of fasting and nonfasting lipid levels for classifying participants into appropriate ASCVD risk categories was high (94.8%).

CONCLUSIONS AND RELEVANCE: Measurement of nonfasting and fasting lipid levels yields similar results in the same individuals for association with incident coronary and ASCVD events. These results suggest that routine measurement of nonfasting lipid levels may help facilitate ASCVD risk screening and treatment, including consideration of when to initiate statin therapy.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Mora S, Chang CL, Moorthy MV, et al. Association of Nonfasting vs Fasting Lipid Levels With Risk of Major Coronary Events in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm. JAMA Intern Med. 2019. PMID: 31135812. doi:10.1001/jamainternmed.2019.0392

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。